New publication supports the use of caldolor® in newborn pediatric patients

Nashville, tenn. , june 26, 2023 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, today announced the publication of positive results from a clinical study  investigating the safety and pharmacokinetics of caldolor® in newborn infants, published in the journal pediatric drugs 1.
CPIX Ratings Summary
CPIX Quant Ranking